Company news
Scancell Holdings Plc (LSE:SCLP) news
Scancell Holdings Plc news releases on 6ix. Latest, Aug 12, 2014: Synergy of SCIB1 with checkpoint inhibitors
Press releases — page 6
Synergy of SCIB1 with checkpoint inhibitors
August 12, 2014
DNA ImmunoBody Patent Granted in United States
June 6, 2014
Update on Phase 1/2 trial of SCIB1 in melanoma
June 2, 2014
Presents latest SCIB1 data at ASCO
May 15, 2014
Dr Sally Adams to Join as Development Director
May 1, 2014
Scancell to present SCIB1 at AACR
April 4, 2014
8mg Higher Dose SCIB1 Study On Track
March 21, 2014
Publication of Moditope Patent
February 18, 2014
SCIB1 Granted FDA Orphan Drug Status
February 11, 2014
Nottingham Technology Grant
January 6, 2014
Nottingham Trent University Cancer Protein Study
December 16, 2013
DNA ImmunoBody Patent Granted in Japan
December 12, 2013
New data for SCIB1 in metastatic melanoma
December 9, 2013
Re Agreement with Ichor
November 18, 2013
AGM Statement
November 1, 2013
Investor Update
October 1, 2013
Investor Update Agenda
September 24, 2013
Investor Day
September 10, 2013
DNA ImmunoBody Patent Granted in first market
September 3, 2013
Inclusion on Frankfurt Stock Exchange
August 20, 2013
Result of General Meeting
August 1, 2013
Result of Open Offer
July 26, 2013
Annual Financial Report
July 10, 2013
Proposed Firm Placing and Open Offer
July 9, 2013
Re: The Journal of Clinical Investigation Paper
March 14, 2013
ImmunoBody patent approved for grant in Japan
February 6, 2013
Update on patient recruitment in clinical trial
January 29, 2013
SCIB1 Trial-Higher Dose Allowed in Phase 1/2 Trial
December 12, 2012
Update on SCIB1 Phase 1/2 clinical trial
December 6, 2012
Notice of Results and Share Price Movement
October 8, 2012
Change of Advisers
October 3, 2012
Market Update
August 20, 2012
Moditope Vaccine Technology Platform
August 15, 2012
Long Term Treatment Approval
June 19, 2012
Vesting of Ichor Options
May 25, 2012
SCIB1 Update
May 2, 2012
SCIB1 Trial Update
April 17, 2012
Notice of Investor Meeting
March 13, 2012
Patent Approval
March 9, 2012
Half Year Results
January 31, 2012
Holdings in Company
November 17, 2011
Confirmation of GBP2.85 million payment
November 4, 2011
Progress on possible GBP2.85m payment
October 25, 2011
SCIB 1 Patent Awarded
October 20, 2011
Appointment of Director
August 18, 2011
SCIB1: Safety Review and Dose Escalation
August 17, 2011
AGM & EGM Statement
July 25, 2011
Change of Board Structure
June 30, 2011
Development of new vaccine for treating lung ca...
June 30, 2011
Placing to raise £1.73 million
June 30, 2011